NO20073025L - Dibenzylaminforbindelser og derivater - Google Patents
Dibenzylaminforbindelser og derivaterInfo
- Publication number
- NO20073025L NO20073025L NO20073025A NO20073025A NO20073025L NO 20073025 L NO20073025 L NO 20073025L NO 20073025 A NO20073025 A NO 20073025A NO 20073025 A NO20073025 A NO 20073025A NO 20073025 L NO20073025 L NO 20073025L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- derivatives
- levels
- cholesterol
- triglycerides
- Prior art date
Links
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 title abstract 2
- 238000008214 LDL Cholesterol Methods 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108010023302 HDL Cholesterol Proteins 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Dibenzylamin forbindelser og derivater, farmasøytiske sammensetninger som inneholder slike forbindelser og anvendelse av slike forbindelser for å heve visse plasmalipid nivåer, som inkluderer høytetthets lipoprotein-kolesterol og å redusere visse andre plasma lipid nivåer, slik som LDL-kolesterol og triglyserider og følgelig behandle sykdommer som forverres ved lave nivåer av HDL kolesterol og/eller høye nivåer av LDL-kolesterol og triglyserider, slike som aterosklerose og kardiovaskulære sykdommer hos noen pattedyr, som inkluderer mennesker.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63043404P | 2004-11-23 | 2004-11-23 | |
| US71561705P | 2005-09-12 | 2005-09-12 | |
| PCT/IB2005/003500 WO2006056854A1 (en) | 2004-11-23 | 2005-11-21 | Dibenzyl amine compounds and derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073025L true NO20073025L (no) | 2007-08-20 |
Family
ID=35828305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073025A NO20073025L (no) | 2004-11-23 | 2007-06-13 | Dibenzylaminforbindelser og derivater |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20090239865A1 (no) |
| EP (1) | EP1817297A1 (no) |
| JP (1) | JP2008520645A (no) |
| KR (1) | KR20070069213A (no) |
| AP (1) | AP2007003980A0 (no) |
| AR (1) | AR053784A1 (no) |
| AU (1) | AU2005308584A1 (no) |
| BR (1) | BRPI0518476A2 (no) |
| CA (1) | CA2589322A1 (no) |
| CR (1) | CR9089A (no) |
| EA (1) | EA200700924A1 (no) |
| GT (1) | GT200500339A (no) |
| IL (1) | IL183133A0 (no) |
| MA (1) | MA29039B1 (no) |
| MX (1) | MX2007006137A (no) |
| NL (1) | NL1030486C2 (no) |
| NO (1) | NO20073025L (no) |
| PE (1) | PE20061124A1 (no) |
| TN (1) | TNSN07200A1 (no) |
| TW (1) | TW200630350A (no) |
| UY (1) | UY29222A1 (no) |
| WO (1) | WO2006056854A1 (no) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006073973A2 (en) | 2004-12-31 | 2006-07-13 | Reddy Us Therapeutics, Inc. | Novel benzylamine derivatives as cetp inhibitors |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| WO2007041494A2 (en) * | 2005-09-30 | 2007-04-12 | Merck & Co., Inc. | Cholesteryl ester transfer protein inhibitors |
| JP4981814B2 (ja) * | 2005-12-28 | 2012-07-25 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 選択的なベンジルアミン誘導体およびコレステロールエステル転写タンパク質抑制剤としてのその有用性 |
| JP2009522224A (ja) * | 2005-12-29 | 2009-06-11 | ノバルティス アクチエンゲゼルシャフト | コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体 |
| UY30117A1 (es) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| US7919506B2 (en) * | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US8383660B2 (en) * | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| WO2007128568A1 (en) | 2006-05-10 | 2007-11-15 | Novartis Ag | Bicyclic derivatives as cetp inhibitors |
| RU2008148600A (ru) * | 2006-05-11 | 2010-06-20 | Новартис АГ (CH) | Производные бензиламина в качестве ингибиторов сетр |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| JP5244095B2 (ja) * | 2007-04-13 | 2013-07-24 | 興和株式会社 | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 |
| JP4846769B2 (ja) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4834699B2 (ja) * | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CA2722582A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf. | Biaryl pde4 inhibitors for treating inflammation |
| KR20100098653A (ko) | 2007-11-21 | 2010-09-08 | 디코드 제네틱스 이에이치에프 | 염증의 치료를 위한 바이아릴 ｐｄｅ４ 억제제 |
| CN101952244B (zh) * | 2008-02-01 | 2014-11-05 | 潘米拉制药公司 | 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂 |
| UA98839C2 (en) * | 2008-02-01 | 2012-06-25 | Панмира Фармасьютикалз, Ллк. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体アンタゴニスト |
| WO2009145989A2 (en) | 2008-04-02 | 2009-12-03 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) * | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| WO2010059838A2 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| CN102596902A (zh) | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
| CA2782085A1 (en) | 2010-01-06 | 2011-07-14 | Panmira Pharmaceuticals, Llc | Dp2 antagonist and uses thereof |
| RU2013114390A (ru) | 2010-08-31 | 2014-10-10 | СНУ Ар энд ДиБи ФАУНДЕЙШН | Применение фетального репрограммирования посредством ppar-дельта-агониста |
| ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
| US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
| MX352074B (es) | 2011-09-27 | 2017-11-08 | Dr Reddys Laboratories Ltd | Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. |
| US9717714B2 (en) | 2012-12-19 | 2017-08-01 | Merck Sharp & Dohme Corp. | Spirocyclic CETP inhibitors |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN115677572B (zh) * | 2021-07-29 | 2024-05-28 | 武汉思瓴生物科技有限公司 | 氟代酰胺类衍生物、药物组合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1360172A1 (en) * | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
| JP2003221376A (ja) * | 2001-11-21 | 2003-08-05 | Japan Tobacco Inc | Ｃｅｔｐ活性阻害剤 |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
| CN1942428A (zh) * | 2004-04-13 | 2007-04-04 | 默克公司 | Cetp抑制剂 |
-
2005
- 2005-11-21 PE PE2005001363A patent/PE20061124A1/es not_active Application Discontinuation
- 2005-11-21 JP JP2007542159A patent/JP2008520645A/ja not_active Withdrawn
- 2005-11-21 AP AP2007003980A patent/AP2007003980A0/xx unknown
- 2005-11-21 MX MX2007006137A patent/MX2007006137A/es unknown
- 2005-11-21 EA EA200700924A patent/EA200700924A1/ru unknown
- 2005-11-21 US US11/719,885 patent/US20090239865A1/en not_active Abandoned
- 2005-11-21 AU AU2005308584A patent/AU2005308584A1/en not_active Abandoned
- 2005-11-21 TW TW094140833A patent/TW200630350A/zh unknown
- 2005-11-21 CA CA002589322A patent/CA2589322A1/en not_active Abandoned
- 2005-11-21 AR ARP050104864A patent/AR053784A1/es unknown
- 2005-11-21 EP EP05805656A patent/EP1817297A1/en not_active Withdrawn
- 2005-11-21 WO PCT/IB2005/003500 patent/WO2006056854A1/en not_active Ceased
- 2005-11-21 KR KR1020077011611A patent/KR20070069213A/ko not_active Ceased
- 2005-11-21 BR BRPI0518476-2A patent/BRPI0518476A2/pt not_active Application Discontinuation
- 2005-11-22 NL NL1030486A patent/NL1030486C2/nl not_active IP Right Cessation
- 2005-11-22 UY UY29222A patent/UY29222A1/es not_active Application Discontinuation
- 2005-11-23 GT GT200500339A patent/GT200500339A/es unknown
-
2007
- 2007-04-30 CR CR9089A patent/CR9089A/es not_active Application Discontinuation
- 2007-05-10 IL IL183133A patent/IL183133A0/en unknown
- 2007-05-22 TN TNP2007000200A patent/TNSN07200A1/fr unknown
- 2007-05-23 MA MA29936A patent/MA29039B1/fr unknown
- 2007-06-13 NO NO20073025A patent/NO20073025L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL183133A0 (en) | 2007-09-20 |
| WO2006056854A1 (en) | 2006-06-01 |
| KR20070069213A (ko) | 2007-07-02 |
| MX2007006137A (es) | 2007-07-19 |
| TNSN07200A1 (fr) | 2008-11-21 |
| GT200500339A (es) | 2006-06-22 |
| MA29039B1 (fr) | 2007-11-01 |
| EP1817297A1 (en) | 2007-08-15 |
| PE20061124A1 (es) | 2006-10-13 |
| US20090239865A1 (en) | 2009-09-24 |
| UY29222A1 (es) | 2006-06-30 |
| NL1030486C2 (nl) | 2006-10-24 |
| CR9089A (es) | 2007-05-30 |
| AU2005308584A1 (en) | 2006-06-01 |
| EA200700924A1 (ru) | 2007-10-26 |
| TW200630350A (en) | 2006-09-01 |
| BRPI0518476A2 (pt) | 2008-11-18 |
| AP2007003980A0 (en) | 2007-06-30 |
| NL1030486A1 (nl) | 2006-05-24 |
| CA2589322A1 (en) | 2006-06-01 |
| JP2008520645A (ja) | 2008-06-19 |
| AR053784A1 (es) | 2007-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073025L (no) | Dibenzylaminforbindelser og derivater | |
| NO20083642L (no) | Dibenzylaminderivater som CETP-inhibitorer | |
| NO20071510L (no) | 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser | |
| NO20052921L (no) | Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer | |
| WO2006045010A3 (en) | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | |
| NO20070511L (no) | Substituerte heteroaryl- og fenylsulfamoylforbindelser | |
| UY28243A1 (es) | Compuestos de quinolina y qunoxalina | |
| NO20064615L (no) | Substituerte heteroaryl- og fenylsulfamoylforbindelser | |
| AP2002002427A0 (en) | Ppar compounds. | |
| CL2012001124A1 (es) | Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl. | |
| AP2002002426A0 (en) | Ppar agonists | |
| WO2012100229A3 (en) | Compositions and methods for cardiovascular disease | |
| NO20083641L (no) | Dibenzylaminforbindelser, samt derivater derav | |
| EA200801008A1 (ru) | Гипохолестеринемические соединения | |
| WO2009027785A3 (en) | 1, 3-oxazole derivatives as cetp inhibitors | |
| TW200616964A (en) | Quinoline compounds | |
| MX2007010243A (es) | Compuestos de 1,1,1-trifluoro-3-[(bencil)-(pirimidin-2-il)-amino]- propan-2-ol sustituidos. | |
| WO2008070496A3 (en) | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases | |
| NO20070140L (no) | Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi | |
| ECSP088730A (es) | Derivados de dibencilamina como inhibidores de cetp | |
| DOP2004000863A (es) | Compuestos de quinolina y quinoxalina | |
| CU20080164A7 (es) | Compuestos y derivados de dibencilamina | |
| UY27158A1 (es) | Compuestos de ppar | |
| DOP2002000327A (es) | Agonistas de ppar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |